Physician profile

Ashraf Mn Ali

Child & Adolescent Psychiatry · Rancho Cucamonga, CA

NPI 1396906616

$525.83

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$29.03

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Janssen Pharmaceuticals, INC $117.34 2019
Otsuka America Pharmaceutical, INC. $76.28 2019
Boehringer Ingelheim Pharmaceuticals, INC. $70.55 2020-2021
Sunovion Pharmaceuticals INC. $63.38 2019
Vanda Pharmaceuticals INC. $51.30 2019
Neurocrine Biosciences, INC. $51.27 2019
Ardelyx, INC. $29.03 2024 Ibsrela
Indivior INC. $25.54 2019
Noven Therapeutics, LLC $21.43 2020
Teva Pharmaceuticals USA, INC. $19.71 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Ashraf Mn Ali

$525.83

in general payments reported 2019-2025

Years
2019-2024
Top company
Janssen Pharmaceuticals, INC

https://glasscript.com/doctor/108355/ashraf-mn-ali

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.